Michael Jon Brown Sells 1,700 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $64.85, for a total value of $110,245.00. Following the transaction, the executive vice president owned 112,904 shares of the company’s stock, valued at $7,321,824.40. The trade was a 1.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

DexCom Price Performance

NASDAQ:DXCM opened at $67.27 on Friday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The firm has a market capitalization of $25.89 billion, a price-to-earnings ratio of 32.03, a P/E/G ratio of 1.32 and a beta of 1.48. The stock’s 50 day moving average price is $70.51 and its two-hundred day moving average price is $68.21. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.45 EPS. On average, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Institutional Investors Weigh In On DexCom

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom in the second quarter valued at about $26,000. Reflection Asset Management acquired a new stake in DexCom in the 4th quarter worth about $25,000. SJS Investment Consulting Inc. boosted its holdings in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the period. Financial Consulate Inc. bought a new stake in DexCom in the 3rd quarter valued at about $29,000. Finally, CVA Family Office LLC boosted its holdings in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Piper Sandler restated an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Truist Financial reaffirmed a “buy” rating and set a $80.00 target price (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. BTIG Research reiterated a “buy” rating and issued a $85.00 price target on shares of DexCom in a research note on Monday, March 9th. Finally, Evercore assumed coverage on shares of DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.50.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.